Advertisement

Topics

Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer

19:00 EST 6 Feb 2013 | National Cancer Institute

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an analysis of a large, randomized clinical trial.

Original Article: Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer

NEXT ARTICLE

More From BioPortfolio on "Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cervical Cancer
Cervical cancer is a malignant neoplasm of the cervix uteri or cervical area. Symptoms include vaginal bleeding, but may not present until later stages of the cancer. Cervical cancer can be treated using surgery (including local excision) in early stages...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...